** BTIG starts coverage on Tvardi Therapeutics TVRD.O with "buy" rating and $55 PT, 108.7% upside to stock's last close
** Brokerage says TVRD is "presumptive first mover" in developing STAT3 inhibitors for fibrotic diseases, targeting previously "undruggable" protein with "highly validated and well-characterized" profile
** Fibrotic diseases are type of lung illnesses
** Co's lead drug, TTI-101, has potential to be "breakthrough therapy" that can actually reverse these diseases, rather than just slowing their progression, BTIG says
** Says early results from clinical trial are "unusually persuasive", with over 50% of patients showing improvement - outcome that is "unlikely without an active therapy"
** Upcoming mid-stage trial data expected in 2H25 could be major catalyst for stock, BTIG says
** As of last close, stock up 43.5% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。